Abstract:Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre-pandemic strains. Alternatively, other approaches aim toward eliciting a broader immune response capable of conferring protection against the diversity of currently circulating seasonal influenza strains.In this review, the most promising under-development universal vaccine approaches are discussed with an emphasis on those targeting the HA glycoprotein. In particular, their strengths and potential short-comings are discussed. Ultimately, the upcoming clinical evaluation of these universal vaccine approaches will be fundamental to determine their effectiveness against preventing influenza virus infection and/or reducing transmission and disease severity.

A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A

Opportunities and challenges for T cell-based influenza vaccines

Towards a universal influenza vaccine: different approaches for one goal

Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus

Immunogenic Stimulus for Germline Precursors of Antibodies That Engage the Influenza Hemagglutinin Receptor-Binding Site.

Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Fighting flu: novel CD8+ T‐cell targets are required for future influenza vaccines

Progress towards the Development of a Universal Influenza Vaccine

Vaccine approaches conferring cross-protection against influenza viruses

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Influenza vaccine: progress in a vaccine that elicits a broad immune response

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Influenza vaccines: Past, present, and future

The human antibody response to influenza A virus infection and vaccination

Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine

A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus

Influenza and the challenge for immunology

H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination.

Structural Vaccinology: Structure-Based Design of Influenza A Virus Hemagglutinin Subtype-Specific Subunit Vaccines.